EPHX4 and cancer: Furthermore, a pan-cancer analysis that combined data from the TCGA and GTEx databases indicated significant overexpression of EPHX4 in 22 different tumor types, including LUAD, alongside notable underexpression in 2 tumor types; however, variations in other tumor types did not achieve statistical significance (Figure 1G).